Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819380 | 0.87 | P2RX7 (0.39) | P2RX7KDM4ESMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL6819263 | 0.82 | P2RX7 (0.37) | P2RX7KDM4ESMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL6816727 | 0.82 | P2RX7 (0.33) | P2RX7CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6819881 | 0.81 | KIF11 (0.39) | P2RX7KDM4ESMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL6820234 | 0.78 | CYP1A2 (0.45) | HSD17B10CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6816210 | 0.75 | KDM4E (0.35) | P2RX7KDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL6819899 | 0.73 | P2RX7 (0.36) | P2RX7CYP1A2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6816117 | 0.69 | P2RX7 (0.36) | P2RX7KDM4ESMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL7613484 | 0.69 | ALDH1A1 (0.43) | KDM4EHSD17B10CYP1A2ALDH1A1CYP2C9 | |
| SCHEMBL6564259 | 0.69 | ACP3 (0.46) | P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995734-B1 | Method for production of halogen-containing aromatic compound | NIPPON CATALYTIC CHEM IND (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6433231-B2 | BROMINATION THE CORRESPONDING NAPHTHALENE HALOGEN COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | NIPPON SHOKUBAI CO., LTD., A JAPAN CORPORATION | 2001-11-29 | — | — | US | disclosed |
| US-6288290-B1 | BROMINATION AND PHOTOBROMINATION OF AROMATIC COMPOUNDS | NIPPON SHOKUBAI, CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-0995734-A1 | Method for production of halogen-containing aromatic compound | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010045350-A1 | Method for production of halogen-containing aromatic compound | CBR1, CBR3, DCXR | P2RX7 270/4885KDM4E 2637/4885SMN1; SMN2 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.